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The fat mass and obesity-associated (FTO) gene was placed center stage when common intronic variants
within the gene were robustly associated with human obesity. Murine models of perturbed Fto expression
have shown effects on body weight and composition. However, a clear understanding of the link between
FTO intronic variants and FTO activity has remained elusive. Two recent reports now indicate that obesity-
associated SNPs appear functionally connected not with FTO but with two neighboring genes: IRX3 and
RPGRIP1L. Here, we review these new findings and consider the implications for future analysis of GWAS
hits.When first cloned in 1999, Fto was postulated to have a role in
programmed cell death and development. It was identified in
the study of the ‘‘fused toe’’ (Ft) mouse, a model organism
created by insertional mutagenesis that had a 1.6 Mb deletion
on chromosome 8 (van der Hoeven et al., 1994). Mice heterozy-
gous for the Ft mutation developed fusion of the first to fourth
toes of the forelimbs and thymic hyperplasia (Peters et al.,
1999). This deletion eliminated six genes (Peters et al., 2002)
and three members of the Iroquois gene family (Irx3, Irx5, and
Irx6) that form the IrxB cluster, as well as three other genes
(Fts, Ftm, and Fto), which, at the time, were poorly characterized.
Fts was initially called ‘‘Ft1,’’ being the first of the three to be
identified; the second proved to be an elusive sequence to char-
acterize technically, so it was labeled the Fantom (Ftm); the third
gene was named ‘‘Fatso’’ (Fto) because of its large size (Fischer
et al., 2008).
Setting a theme that plays throughout the studies of Fto
biology, subsequent studies of the Ft mouse were taken up in
trying to determine which of the affected genes in the larger
deleted locus were responsible for the component parts of the
diverse phenotypes seen in the animal. Furthermore, these
initially mysterious genes underwent name changes to reflect
evolving knowledge. Ftm was found to be a novel basal body
protein of cilia involved in Hedgehog (Hh) signaling (Vierkotten
et al., 2007). Sequence analysis revealed Ftm to be highly homol-
ogous to RPGRIP1 (retinitis pigmentosa GTPase regulator inter-
acting protein 1, a gene encoding a protein with a role in photo-
receptor cells of the eye), and it was renamed Rpgrip1-like
(Rpgrip1l). In mice, inactivation of Rpgrip1l causes a multiorgan
syndromic phenotype with cerebral, renal, and hepatic defects
(Vierkotten et al., 2007), while mutations in RPGRIP1L are the
cause of a group of developmental disorders such as Joubert
syndrome type B and Meckel syndrome (Delous et al., 2007).
With the coming of age of technologically advanced genetic
association studies, Fto underwent a more subtle, but no less
significant, name change, with the roots of the labeling acronym
reflecting its new association with obesity and metabolism.
A Star Is Born
In the first half of 2007, three independent studies demonstrated
a strong association between genetic variance within FTO and710 Cell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc.human obesity. The gene name morphed into ‘‘fat mass and
obesity associated,’’ and the metabolic community had, at
last, an example of common genetic variance with robust evi-
dence of association with obesity in the general population.
The Frayling et al. (2007) study initially set out to search for
type 2 diabetes mellitus susceptibility genes. In doing so, they
identified a common variant in the FTO gene that, indeed, predis-
posed to diabetes but through an effect on body mass index
(BMI). This effect on BMI was driven entirely through fat mass
and, although not detectable at birth, was fully present by the
age of 7 years and persisted through adulthood (Frayling et al.,
2007). The major signal for association with BMI was a cluster
of SNPs in the first intron of FTO. All BMI-associated SNPs
were highly correlated with each other, but SNP rs9939609, hav-
ing the highest genotyping success rate, was studied further.
The 16% of adults who were homozygous for the risk allele A
weighed close to 3 kg more and had 1.67-fold increased odds
of obesity when compared with those not inheriting a risk allele
(Frayling et al., 2007).
Complementing and confirming these findings, a contempora-
neous report by Dina et al. (2007) took a different approach to
discover this association, initially setting out to analyze the distri-
bution of 48 neutral SNPs in a case-control obesity cohort
collected from French individuals of European ancestry. While
47 of the 48 showed uniform distribution, the T allele of SNP rs
1121980 (located within the first intron of FTO) was strongly
associated with severe adult obesity. Building on this observa-
tion, Dina et al. demonstrated that several SNPs in the FTO locus
were highly associated not only with severe obesity in other
adult, European populations but also with severe childhood
obesity.
The last of this triumvirate undertook a genome-wide associa-
tion study in the genetically isolated population of Sardinia to
identify genetic variants associated with obesity-related quanti-
tative traits (Scuteri et al., 2007). Again, a number of common
variants in FTO were associated with BMI, hip circumference,
and total body weight.
The significant challenges were clear from the beginning. FTO
was widely expressed throughout the body (Frayling et al., 2007;
Dina et al., 2007; Gerken et al., 2007), and, at the time, nothing
was known about function or potential pathways. All of these
Cell Metabolism
Perspectiveinitial reportsmade it clear that therewas no readymechanism to
explain how the predisposing intronic variants affected function
or expression of FTO. Indeed, right from the start, the possibility
that the underlying mechanism involved neighboring genes or
other, as-yet-unidentified, more distant genes was raised.
However, hot on the heels of these initial findings, there fol-
lowed a report that gave some important clues to FTO biology.
Bioinformatics analysis indicated that FTO shared sequencemo-
tifs with Fe(II)- and 2-oxoglutarate-dependent oxygenases, with
assays using recombinant murine Fto showing that the protein
could catalyze Fe(II)- and 2OG-dependent DNA demethylation,
the preferred substrate being 3-methylthymine in DNA. Fto
was also found to be localized to the nucleus and highly ex-
pressed in hypothalamic regions with critical roles for the control
of energy balance in a nutritionally dependent manner (Gerken
et al., 2007).
Subsequently, genome-wide association studies (GWASs) for
obesity-related traits inamyriadofEuropeanancestrypopulations
confirmed that multiple SNPs at the FTO locus were associated
with BMI (Graff et al., 2013; Bradfield et al., 2012; Lindgren et al.,
2009; Meyre et al., 2009; Scherag et al., 2010; Speliotes et al.,
2010; Thorleifsson et al., 2009; Wheeler et al., 2013; Willer
et al., 2009). Many other reports found the association of FTO
SNPs with BMI in non-European-derived populations, including
most populations of Asian ancestry, as well as Hispanic/Latino
populations and Pima Indians (reviewed by Loos and Yeo, 2014).
Studies in populations of African ancestry, in which the FTO
gene shows significant differences in allele frequency and link-
age disequilibrium (LD) patterns, have proven to be insightful.
Although several of the previously identified variants appear
not to have significant association with BMI in these populations,
other intronic variations around the FTO locus (such as
rs3751812 and rs9941349) show strong evidence of association
(Adeyemo et al., 2010; Hassanein et al., 2010). Furthermore, the
most significant value in the report by Peters et al. (2013) came
from a SNP (rs56137030) that had not been highlighted in previ-
ous studies. A recent meta-analysis by Monda et al. (2013) of
data derived from populations of African ancestry also provided
support for shared BMI loci across populations.
The association of FTO SNPswith obesity-related traits in chil-
dren and adolescents was also extended (Bradfield et al., 2012;
Meyre et al., 2009; Scherag et al., 2010). While SNPs in FTO did
not influence birth weight (Horikoshi et al., 2013; Jess et al.,
2008; Kilpela¨inen et al., 2011a), longitudinal studies revealed
that the effect on body weight appeared during early childhood,
reaching its peak at young adulthood (Graff et al., 2013; Hardy
et al., 2010; Sovio et al., 2011).
This initial wave of association studies was soon followed by
reports considering whether FTO SNPs associated with more
specific regulators for energy homeostasis, such as food intake
or physical activity.
Data pointing to a link with food intake began to emerge.
Obesity-associated FTO SNPs were found to be associated
with increased energy intake (Cecil et al., 2008; Speakman
et al., 2008; Timpson et al., 2008), increased intake of dietary
fat (Park et al., 2013; Timpson et al., 2008) or protein (Sonestedt
et al., 2009), increased appetite and reduced satiety (Wardle
et al., 2008, 2009), and loss of control over eating (Tanofsky-
Kraff et al., 2009). This link with food intake was not seen in everystudy; for example, a report by Stutzmann et al. (2009) failed to
find an association of the FTO rs 1421085 C allele with eating
behavior traits in a large European cohort of children and adults.
However, a recent GWAS of macronutrient intake in more than
70,000 individuals identified the BMI-increasing allele of FTO
SNPs as highly significantly associated with increased protein
intake (Tanaka et al., 2013).
Other studies have consistently shown that FTO SNPs are not
associated with physical activity levels (Ahmad et al., 2010;
Franks et al., 2008; Speakman et al., 2008; Vimaleswaran
et al., 2009). However, low physical activity has been reported
to accentuate the effect of FTO risk alleles on obesity in French
adults (Cauchi et al., 2009), with a large-scale meta-analysis of
published and unpublished data of more than 200,000 adults
and 20,000 children (Kilpela¨inen et al., 2011b) concluding that
the association of FTO SNPs with the odds of obesity are
reduced by close to a third in physically active adults. Pheno-
typic variability in BMI for a given FTO genotype was also re-
ported by Yang et al.’s (2012) report highlighting the potential
of environmental modifiers to influence the ‘‘genetic burden’’ of
the FTO risk alleles.
Model Organisms and Fto
The phenotype ofmicewith a global germline loss of Ftowas first
reported in 2009 (Fischer et al., 2009). Fto null mice suffered from
a high perinatal mortality and a postnatal period characterized by
reduction in both body length and body weight, the latter being a
result of reduced fat and lean mass. They were reported to have
both an increase in food intake and an increase inmetabolic rate.
Later analyses of several independent murine models of Fto loss
also confirmed this pattern of postnatal growth retardation, but
one report has shown that, when corrected for alteration in
body composition, there was no difference in energy expendi-
ture in mice globally lacking Fto (McMurray et al., 2013).
In 2010, Cox and colleagues in Harwell, UK, generated mice
globally expressing additional copies of the Fto gene (Church
et al., 2010). This ubiquitous overexpression of Fto increased
body and fat mass, with the obese phenotype more marked on
a high-fat diet. Food intake was significantly increased, but en-
ergy expenditure and physical activity were unaltered in these
mice.
Reports of more specific regional and temporal Fto perturba-
tion soon emerged. Gao et al. (2010) used a conditional allele to
delete Fto in the nervous system. Their findings that this resulted
in similar phenotypes as that of the whole body deletion pointed
to Fto having a crucial role in the central nervous system to regu-
late postnatal growth. Following from the finding that Fto expres-
sion in the arcuate nucleus of the hypothalamus was nutritionally
regulated (Gerken et al., 2007; Stratigopoulos et al., 2011; Porit-
sanos et al., 2011), we targeted this region with stereotactically
delivered adeno-associated virus and demonstrated that over-
expression decreased food intake while knockdown of Fto
increased food intake (Tung et al., 2010).
McMurray et al. (2013) also used a conditional allele to globally
delete Fto at 6 weeks of age. Development in the weeks after
was characterized by a loss of lean mass but an increase in fat
mass (McMurray et al., 2013). Intriguingly, regional deletion of
Fto in mediobasal hypothalamus of adult mice did affect feeding
behavior but did not affect body composition, which isCell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc. 711
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role in controlling lean mass.
Thus, although many questions remained unanswered, from
these animal data at least, it seemed plausible that Fto had a
role in the regulation of body composition and energy balance.
Novel Functions, Unexpected Roles
How then does one to try and link these murine and association
studies with a common molecular mechanism, particularly one
involving the demethylase activity reported by Gerken et al.
(2007)? The family of demethylase enzymes had long been
known to have a role in the repair of methyl lesions in DNA and
RNA (Ougland et al., 2004; Lee et al., 2005) but had little to link
them directly to control of metabolism and body composition.
Further studies followed that confirmed that FTO catalyzed the
demethylation of 3-methylthymine in single-stranded DNA, as
well as 3-methyluracil (3meU) (Gerken et al., 2007; Jia et al.,
2008) and 6-methyl adenosine (6meA) (Jia et al., 2011) in sin-
gle-stranded RNA.
The crystal structure of FTO was resolved and showed an
N-terminal catalytic domain and a C-terminal domain of un-
known function (Han et al., 2010). The specificity for single-
stranded nucleic acids appeared to come from an L1 loop, not
present in other members of the AlkB family, that acted to hinder
double-stranded nucleic acids from entering the catalytic pocket
(Han et al., 2010).
The finding that 6meA, the most commonmodified nucleoside
found in messenger RNA (mRNA) (Desrosiers et al., 1974), was
demethylated by FTO, with 50-fold greater affinity than 3meU
(Jia et al., 2011), gave rise to a hypothesis in which FTO influ-
enced metabolism by posttranscriptional modification of RNA
message. This idea was featured in two studies in 2013 (Hess
et al., 2013; Karra et al., 2013) that explored how FTO’s putative
demethylase action might affect complex human phenotypes.
Fto and Dopamine
Hess et al. (2013) described a role for Fto in controlling the dopa-
minergic circuitry within the midbrain. The idea to explore a pu-
tative Fto-dopamine link came about because the phenotype of
the Fto null mouse closely matched the description of mice lack-
ing dopamine receptor type 2 (D2R) (Sibley, 1999). Their studies
found that Fto null mice responded differently to control animals
after administration of cocaine, a drug that can inhibit the dopa-
mine transporter and, thereby, increase synaptic dopamine
levels. In response to cocaine, Fto-deficient mice failed to
show an increase in locomotor activity; had less c-fos activation
in the ventral tegmental area, caudate putamen, and nucleus ac-
cumbens; and had a blunted increase in extracellular dopamine.
Further studies, in which pharmacological agents known to act
through the dopaminergic system were administered to a range
of genetically engineered animals, confirmed that Fto loss im-
pairs D2R-like signaling in a cell-autonomous manner.
An elegant component to this story combinedmethylated RNA
immunoprecipitation with bioinformatics to try and link these
novel findings with previous data on the demethylase action of
FTO. By identifying transcripts containing m6A in midbrains
and striatum from control and Fto-deficient mice, Hess et al.
(2013) found that the transcripts selectively methylated in Fto
null micewere disproportionately linked to synaptic transmission712 Cell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc.and cell signaling. Furthermore, in the absence of Fto, both
mRNA and protein of key regulators of dopaminergic neuron ac-
tivity showed increased methylation.
The identification of FTO-specific adenosine methylation on a
subset of mRNA involved in dopamine signaling pathway was
the first in vivo demonstration of FTO as a functional m6A deme-
thylase. These observations also provided the first indication
that FTO may play a tissue- or even cell-type-specific role by
regulating specific subsets of mRNA relevant to the physiolog-
ical function of the tissue, and this might help explain how a sin-
gle protein can appear to have such widespread influence over a
range of seemingly disparate functions.
Ghrelin and the Brain: Is FTO the Missing Link?
The findings of the Hess et al. (2013) study gave Fto a potential
role in the reward systems. Following shortly afterward, a study
by Karra et al. (2013) pursued a mechanistic link between FTO
SNPs and gut peptides. They hypothesized that FTO variants
might not only influence circulating levels of hormones known
to have a role in appetitive behavior but might also affect the
neuronal response to food cues.
Their studies focused on small numbers of young, normal-
weight volunteers divided into two matched groups on the basis
of their genotype at the rs9939609 locus, either high risk (AA) or
low risk (TT). Compared to TT subjects, after a test meal, the AA
group was reported to have a less marked fall in acyl ghrelin and
an attenuated suppression in a visual analog hunger score.
Analysis of mRNA from peripheral blood cells after a period of
fasting showed that subjects with the AA genotype had, in com-
parison to the TT group, a 1.5-fold increase in FTO expression, a
2.5-fold increase in ghrelin precursor GHRL mRNA abundance,
and a reduction in m6A methylation of ghrelin mRNA. fMRI anal-
ysis showed between-genotype differences in a number of brain
regions recognized to have roles in energy homeostasis and
reward related activity.
A further potential link to ghrelin was suggested by data from
in vitro studies where FTO overexpression increased not only
ghrelin and ghrelin O-acyltransferase mRNA but also total and
acyl ghrelin concentrations in cell lysates. FTO overexpression
was also reported to reduce m6A methylation of ghrelin mRNA.
These data led Karra et al. (2013) to the suggestion that the as-
sociation of FTO risk allele with food intake may be mediated
through ghrelin, with the risk allele increasing FTO expression,
which, in turn, reduces m6A ghrelin mRNA demethylation and,
thereby, alters ghrelin production. The differential responses
on fMRI observed in subjects with SNP were certainly striking
because such phenomena have only been demonstrated previ-
ously in situations with drastic physiological differences (De Silva
et al., 2012), such as comparing lean versus obese individuals or
fed versus fasted state, or in the exogenous administration of
appetite-modulating hormones (e.g., ghrelin, PYY, GLP-1, and
leptin).
While this work is of interest, it is worth noting that leucocytes
are not recognized as the natural home for understanding gut
hormone biology, and the sizeable changes in mRNA levels in
white cells were not reflected in differences in the amount of
circulating active acyl-ghrelin seen in the fasted state. Although
there aremeasurable relative changes in white cell levels, the ab-
solute contribution from these cells to total biological active
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all, risk genotype affects ghrelin expression and production in
the stomach andwhether what is happening in a leucocyte bears
any relationship to what might be happening within the antrum of
the stomach. Additionally, it is worth noting that several studies
have failed to reveal any influence of the FTO genotype on
mRNA level of FTO; although mRNA expression of FTO in adi-
pose tissue has been shown to be greater in obese individuals,
this difference did not extend to FTO expression in blood cells.
The fact that mice globally lacking Fto have unchanged levels
of acylated ghrelin in both the fed and fasted states also
suggests that Fto levels contribute little to circulating levels of
ghrelin.
Loss-of-Function Mutations in Humans
Despite all these emerging data, there remained the recurring
uncertainty of what these findings brought to our greater under-
standing of human disease, the primary driver for undertaking
the genetic studies in the first place.
Important data on the potential consequences of FTO loss in
humans came from a study of a consanguineous family in which
affected individuals presented with a previously unreported
autosomal-recessive syndrome characterized by polymalforma-
tion and childhood mortality (Boissel et al., 2009). Genome-wide
autozygosity screening identified a unique region of shared ho-
mozygosity on chromosome 16q12. Further genotype and
haplotype analyses reduced the critical region to a 6.5 Mb inter-
val encompassing 28 genes. After sequencing coding regions
and splice junctions of all known and putative genes in this linked
region, the onlymutation foundwas a homozygous single-nucle-
otide variation at complementary DNA position 947 within the
FTO gene. Affected individuals carried a homozygous R316Q
mutation in FTO, with loss of this highly conserved arginine res-
idue rendering FTO enzymatically null in two different in vitro as-
says; the first based on the conversion of the 2-oxoglutarate to
succinate and the second based on the ability of FTO to demeth-
ylate 3-methylthymine in DNA. The affected individuals homozy-
gous for a catalytically inactive FTO also had, like Fto null mice,
an early growth retardation phenotype but, unlike the Fto null
mice, also had developmental abnormalities in the central ner-
vous or cardiovascular systems. These differences are not
readily explained, and the molecular mechanisms whereby the
mutant FTO leads to the severe phenotype observed these
patients remain unknown. However, it may be that the point mu-
tation in FTO has deleterious gain-of-function effects and/or
dominant-negative interference with other biochemical pro-
cesses that are not seen with the complete deficiency seen in
the Fto null mouse.
What of other members of this extended family? Fto+/ mice
were considered to be resistant to diet-induced obesity (Fischer
et al., 2009), so could heterozygous carriage of this deleterious
R316Q mutation actually protect against obesity? This also re-
mains uncertain because, although this report comments that
none of the parents of the affected children were obese, detailed
phenotypic data on the extended family has not been reported.
Other studies have gone on to investigate whether nonsynon-
ymous variants of FTOmight be enriched in either lean or obese
subjects. Meyre et al. (2010) sequenced entire FTO coding re-
gions in both subjects with severe obesity and in individualswith lifelong leanness. Interestingly, nonsynonymous mutations
were equally common in both the obese and lean cohorts.
Furthermore, heterozygous mutations that severely impaired
enzymatic activity of FTO were found in both lean and obese
subjects who were otherwise clinically unremarkable.
Other studies in lean and obese cohorts of children brought
similar findings. In both African American and Chinese Han pop-
ulations, variants were identified in FTO, but the overall fre-
quencies were similar in case and control, with none conferring
risk of obesity (Deliard et al., 2013; Zheng et al., 2013).
Taken in isolation, these human data fall some way short of a
compelling case for FTO being the candidate mediator of the
obesity association. Murine data indicate that an increase in
Fto expression could potentially lead to obesity, but, to date,
only deleterious point mutations have been described in obese
patients. However, it may be that there are as-yet-uncharacter-
ized patients in other cohorts with genetically deleterious muta-
tions leading to complete loss of FTO. For example, such an
individual may, if one were to phenocopy the mouse model of
Fto deficiency, present initially as a ‘‘failure to thrive’’ and there-
after be noted to be of small stature.
An Interesting Neighborhood
As outlined earlier, the initial FTO intronic associations, followed
by identification of association SNPs in intron 3 (To¨njes et al.,
2010) and intron 8 (Adeyemo et al., 2010), set in train a plethora
of studies based around Fto biology. However, other groups
took a different path, with the Leibel group, in particular,
choosing to focus onRpgrip1l as being the potential mechanistic
link (Stratigopoulos et al., 2008, 2011). They initially took an
in silico bioinformatics approach to focus on two intronic SNPs
(rs17817449 and rs8050136) and predicted that they were
located in a putative binding site for the transcription factor
Cutl-like 1 (CUTL1), also known as cut-like homeobox1 (CUX1)
(Stratigopoulos et al., 2008). CUTL1 acts as a transcriptional
repressor by displacing activators (Skalnik et al., 1991) and/or
by recruitment of histone deacetylase 1 (Mailly et al., 1996). Initial
in vitro data were promising. In chromatin immunoprecipitation
of DNA from human fibroblasts using a CUTL1-specific anti-
body, a 90-base-pair fragment that included rs8050136 was
precipitated. Furthermore, small interfering RNA-mediated
reduction of Cutl1 by 70% resulted in FTO expression
decreasing by 90% and RPGRIP1L by 65%.
Having raised the possibility that both genes were regulated
by CUTL1/CUX1 via a single regulatory site in the first intron of
FTO, Leibel’s group looked, in more detail, at the role of this tran-
scription factor on the different isoforms (the larger P200 and the
smaller p100 isoform, generated from p200 by enzymatic
cathepsin L activity) (Stratigopoulos et al., 2011).
A series of detailed biochemical and promoter analysis exper-
iments led to a proposed mechanism whereby, together, FTO,
RPGRIP1L, andCUX1 facilitate the leptin responsewithin the hy-
pothalamic arcuate nucleus and thereby affect food intake. The
model proposed that reduced circulating leptin, as seen in nega-
tive energy balance, results in the reduced enzymatic processing
of CUX1 P200 and decreased CUX1 P110 protein levels. In turn,
this change in transcription factor isoform ratio decreases
RPGRIP1L and FTO expression, reducing leptin signaling
through an alteration in leptin receptor recruitment at the ciliumCell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc. 713
Figure 1. Increasing Functional Complexity
around the FTO Locus
(A) Emerging data indicate that the links between
intronic variance within FTO and body composi-
tion are mediated through functional interactions
with neighboring genes. The first intron of FTO
contains a binding site for the transcription factor
CUX1 which, through regulation of RPGRIP1L
expression, modulates leptin receptor localization
within neurons. This intron also contains an
enhancer sequence which directly binds to the
promoter of IRX3.
(B) Summary of data on FTO, RPGRIP1L, and IRX3
from human genetic and murine model studies.
Data on IRX3 are notable in that eQTL mapping
demonstrates an association of obesity-linked
SNPS with IRX3 expression.
Cell Metabolism
Perspectiveand thereby increasing the drive to eat. The proposed model
goes on to suggest that, because P110 has reduced affinity for
the rs8050136 obesity-risk A allele but higher affinity for the pro-
tective C allele, individuals with the C allele would have higher
FTO and RPGRIP1L expression and be relatively more leptin
sensitive (Figure 1A).
Building on their previous findings, this group has more
recently published a detailed metabolic phenotype of mice lack-
ing one copy of Rpgrip1l (Stratigopoulos et al., 2014). As noted
previously, homozygous mutations in Rpgrip1l led to significant
developmental anomalies (Vierkotten et al., 2007), but
Rpgrip1l+/mice had a small but statistically significant 10% in-
crease in bodyweight demonstrable by 10weeks old (Figure 1B).
Analysis of older animals showed this to be driven by an increase
in fat but not lean mass. By 19 weeks old, male mice had an in-
crease in both fat and lean mass, with absolute food intake cor-
rected for different body compositions showing Rpgrip1l+/ to
be hyperphagic.
In Rpgrip1l+/mice, an acute leptin dosewas reported to show
a diminished Stat 3 response within the hypothalamus, and an
antibody-based analysis showed a reduction of leptin receptor
in the vicinity of the cilia.
This group went on to look at fibroblasts from healthy human
controls and from a patient with Jouberts syndrome to further714 Cell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc.determine how RPGRIP1L interacts with
the leptin receptor. When leptin receptors
were transfected into control fibroblasts,
they correctly localized to the cilium
with leptin stimulation, and there was a
dose-dependent increase in Stats 3
phosphorylation. In contrast, there was
both perturbed localization and dimin-
ished signaling in RPGRIP1L-deficient
fibroblasts.
They concluded that alteration in leptin
receptor signaling, brought about as a
direct consequence of alteration in the
function of primary cilium, accounted for
the increase in fat mass of Rpgrip1l+/
mice. These model organism studies
are presented as further supportive evi-
dence that individuals with obesity riskA allele at rs8050136 have reductions in both RPGRIP1L and
FTO expression due to reduction on p110 at cognate CUX1
binding, causing diminished leptin signaling, increased food
intake, and adiposity.
Disorders of ciliary biology have long been linked to ‘‘syn-
dromic obesity,’’ and these data from the Leibel group now raise
the intriguing possibility of primary cilia having a role in common
forms of obesity (Stratigopoulos et al., 2008, 2011). However,
there remains still that elusive, direct connection between
obesity-associated variants and expression of the gene in ques-
tion: in particular, whether in humans the number of copies of the
risk allele associates with changes of expression of RPGRIP1L
and FTO, not only in the direction predicted by the model but
also in physiologically relevant tissue.
IRX3: Another Interesting Neighbor
Irx3was one of the initial genes identified within the Ft region but
initially did not attract as much attention as its neighbors did. A
report by Ragvin et al. (2010) reignited interest in its relationship
with FTO. This group focused on the fact that the FTO LD block
appeared to contain numerous highly conserved noncoding ele-
ments (HCNEs) and used computational analysis to determine if
these potential regulatory elements might affect target genes
elsewhere.
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HCNE within FTO was IRX3 and, using sequences from the
obesity-associated FTO LD block in a zebrafish-based, green
fluorescent protein reporter assay, found that expression pat-
terns matched those of IRX3. As IRX3 is highly expressed in
pancreas, theywent on to suggest that at least some of the effect
of the FTO locus on susceptibility to type 2 diabetes may be
through changes in insulin secretion.
Smemo et al. (2014) built on these observations in a compre-
hensive study bringing together evidence from murine, human,
and in vitro studies tomake acompelling case for the involvement
of IRX3 in the association between human obesity and FTO.
They initially investigated cis-regulatory interactions between
FTO and IRX3, using chromatin conformation capture in both
embryonic (mice and zebrafish) and brain tissue from adult
mice. They found that the promoter of Irx3 strongly interacted
with the obesity-associated interval within FTO (Figure 1A).
Results from an in vivo mouse reporter assay that tested hu-
man DNA fragments from the FTO obesity-associated region,
plus data from studies using a human bacterial artificial chromo-
some (BAC) spanning the FTO locus that included its promoter
and the obesity-associated region, clearly showed that IRX3
relied on long-range regulatory input from FTO.
Building on this, a crucial data set missing from previous
studies looked at gene expression levels in the cerebellum, a
site of high expression of both FTO and IRX3. This expression
quantitative trait loci (eQTL) mapping in human brain samples
demonstrated that obesity-linked SNPs such as rs9930506
were associated with IRX3 expression, but not with expression
of FTO, thereby directly linking these variants to IRX3 regulation
(Figure 1B).
Returning tomousemodels, Smemo et al. (2014) reported that
Irx3 null mice had a significant reduction in bodyweight, with less
fat and lean mass compared to wild-type controls. Transcrip-
tional analysis of tissue indicated that there may be increased
sympathetic tone to white adipose tissue, as well as increased
activation of brown adipose, leading to increased energy expen-
diture that contributes to the phenotype seen. Using Cre-lox
technology to express a dominant-negative Irx3 only within the
hypothalamus, this group determined that disrupting Irx3 func-
tion in this region alone recapitulated the metabolic phenotype
of Irx3-deficient mice, thereby supporting the notion that hypo-
thalamic Irx3 is critical in the regulation of body composition.
While this appears to be a compelling set of data, there are still
some areas of uncertainty. The cerebellum is not an area of brain
normally recognized to be involved in the control of energy
expenditure and eQTL analysis using hypothalamic tissue seems
to be an important next step. Furthermore, it would be very inter-
esting to determine if overexpression of Irx3, either globally or in
amore tissue-specific manner, causes obesity in a model organ-
ism. Nevertheless, it would appear that IRX3 has a strong candi-
dacy to be amajormediator of the effects of the common intronic
SNPs on human adiposity.
Discussion
The technological and computational advances that underpin
genetic association studies have brought forth a glut of new in-
formation relevant to a whole host of different human pheno-
types, complex traits, and disease conditions. They have muchpotential to reveal previously unanticipated insights, but as
powerful as the data generated are, there remains the need to
move from an association map into systems, models, and plat-
forms that can be used as tools to get to grips with the biological
architecture of the problem under scrutiny.
So, 7 years on from the initial cluster of reports, how far have
we come with the poster boy of metabolic GWASs?
The data set from animal studies make a decent case that FTO
has a role in the control of energy homeostasis and body compo-
sition. However, there is still much to learn. Whereas initial
studies understandably focused on regions of the brain that
are well characterized to have a role in energy balance, there re-
mains uncertainty not only as to which brain regions are most
critical but also the role Fto may play in peripheral tissues such
as skeletal muscle and fat.
Taken in isolation, the data on FTO from human studies fall
some way short from making a compelling case for FTO as a
candidate mediator of the obesity association. As described
earlier, themost deleteriousmutation has been identified in a sin-
gle extended family with a multisystem phenotype that caused
significant morbidity and early mortality. To date, there appear
to be no reports of deleterious encoding IRX3 mutations being
found in populations of lean or obese; these would be a welcome
addition to the field.
Can we learn wider lessons on how to tackle the ever-growing
list of ‘‘hits’’ from metabolically relevant association studies?
Although murine models have proven invaluable in the study of
monogenic disorders of energy balance and appetitive behavior,
it is naive to assume that murine models alone can give us all the
answers. A comprehensive perspective that clearly lays out
many of the issues surrounding the determination of pathoge-
nicity (or otherwise) of genetic variance can be found in a recent
article by MacArthur et al. (2014), where the primacy of robust
genetic support for causation is rightly emphasized. Further-
more, the recent paper by Smemo et al. (2014), highlighting the
role of IRX3, is an exemplar of how a multilayered combination
of techniques and evidence need to be marshaled together.
The eQTL data presented are key pieces of evidence, and in
the future, when determining if noncoding SNPs are exerting a
functional impact through the alteration of gene expression, a
stronger emphasis on eQTL mapping seems a sensible step for-
ward. Material contained with the GtEX data set, for example,
where a larger number of human tissues have been used for
eQTL mapping (http://www.gtexportal.org/home/), is likely to
be a valuable resource.
Many of the strongest signals coming from GWASs spotlight
genetic loci located some distance from coding exons. Sticking
a pin in the nearest named coding sequence and studying the
consequence of loss of that gene is one very simple way to
move forward. However, if we are to learn anything from the iter-
ative process that the FTO story has been to date, then we learn
that it is only by embracing all the technologies at our disposal
will we be able to move from GWAS signals to biological under-
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